One Mission, Inspired by Patients:
Defeat Cancer.™

In the past three decades, tremendous progress has been made in the fight against cancer, but there is still so much more work to be done. At Deciphera, we remain steadfast in our mission to improve the lives of people living with cancer - and that passion for making a difference extends to the patient groups and communities in which we live and work.

View our pipeline

08/15/24

U.S. Food and Drug Administration Accepts for Priority Review Deciphera’s New Drug Application for Vimseltinib for the Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)

07/18/24

European Medicines Agency Accepts Deciphera’s Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)

06/11/24

Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono)

A targeted approach with extraordinary potential

Kinases are enzymes that help regulate cellular function. When they do not work properly, these enzymes contribute to the growth and spread of many cancers. We design switch-control kinase inhibitors with the goal of potentially improving patient responses to treatment and, ultimately, patient outcomes.

Learn More About Our Discovery Platform

Inspired by patients, driven by science

We come to work every day with a sustained commitment to improving human health - it’s what pushes us to innovate. At Deciphera, we are united in our goal to defeat cancer.

See Who We Are

The future of Deciphera

We are impacting the lives of people living with cancer by addressing key mechanisms of tumor and drug resistance that limit the results of some existing therapies. We have developed a diverse pipeline of drug candidates with the aim of making a difference in patients’ lives.

View Our Pipeline

Discover "The Deciphera Difference"

Learn more

Help us defeat cancer

View open positions

One Mission, Inspired by Patients: Defeat Cancer.™

U.S. Food and Drug Administration Accepts for Priority Review Deciphera’s New Drug Application for Vimseltinib for the Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)

European Medicines Agency Accepts Deciphera’s Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)

Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono)

One Mission, Inspired by Patients:
Defeat Cancer.™